Not provided
Not provided
Not provided
Not provided
Not provided
Insufficient staffing
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a feasibility pilot trial assessing a behavioral intervention for chronic pain among disease-free cancer survivors to decrease long-term opioid dependence.
To assess the feasibility and acceptability of implementing brief Acceptance and Commitment Therapy for chronic pain (ACT-CP) in a Survivorship clinic.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention | Experimental | Acceptance and Commitment Therapy for Chronic Pain (ACT-CP) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Acceptance and Commitment Therapy for chronic pain (ACT-CP) | Behavioral | Delivered virtually via Zoom or via telephone on an individual level; 30-minute sessions led by a trained psychologist and occur weekly for 6 weeks. |
| Measure | Description | Time Frame |
|---|---|---|
| Recruitment yield of participants contacted | Study feasibility will be assessed by tracking the number of patients contacted | 12 Months |
| Recruitment yield of participants consented | Study feasibility will be assessed by tracking the number of participants that consent to enroll in the trial. | 12 Months |
| Recruitment yield number of participants enrolled | Study feasibility will be assessed by recruitment yield, i.e., tracking the number of participants who initiated treatment. | 12 Months |
| Session Attendance | Study feasibility will be assessed by tracking the number of participants attend each intervention session over the course of the 6-week intervention period. | 6 Weeks |
| Participant Satisfaction | Study acceptability will be assessed by administering a post-intervention satisfaction survey which asks about satisfaction with the program including perceived efficacy and suggestions for improvement. | 6 Weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Pain Intensity | Preliminary efficacy of acceptance and commitment therapy for chronic pain (ACT-CP) will be assessed by analyzing change in self-reported pain scores using The Patient-Reported Outcome Measurement Information System short form 3a v1.0 (PROMIS). This tool measures how much a person hurts. | 6 Weeks |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Susan Hong, MD, MPH | Virginia Commonwealth University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Virginia Commonwealth University | Richmond | Virginia | 23219 | United States |
There is no plan to share individual participant data at this time
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010146 | Pain |
| D059350 | Chronic Pain |
| D000072716 | Cancer Pain |
| ID | Term |
|---|---|
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Opioid Use Frequency |
Preliminary efficacy of acceptance and commitment therapy for chronic pain (ACT-CP) will be assessed by self-reported opioid use frequency weekly throughout the intervention period. |
| 6 Weeks |
| Pain interference | Preliminary efficacy of acceptance and commitment therapy for chronic pain (ACT-CP) will be assessed by analyzing pain interference using the PROMIS short form 8a. The PROMIS Pain Interference instrument measures the self-reported consequences of pain on relevant aspects of a person's life and may include the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities. | 6 Weeks |
| Opioid Refill Frequency | Frequency of opioid refills will be assessed via pharmacy records available in patients' EMR | 6 Weeks |